Zafgen, Inc., a biopharmaceutical company, focuses on improving the health and well-being of patients affected by obesity. Beloranib Beloranib, the company’s main product candidate, is a first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. Beloranib is a potent inhibitor of MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism. Strategy The company’s objective is to be a leader in the discovery, development and commercialization of novel therapies to significantly improve the health and well-being of patients affected by obesity. Main elements of the company’s strategy include the following: advancing the clinical development of beloranib in subpopulations of obese patients, including those with rare conditions, where obesity is a co-morbidity of an underlying condition; advancing the clinical development of MetAP2 inhibitors for the treatment of severely obese patients in the general population, including those who are candidates for bariatric surgery; leveraging the knowledge of experienced team of drug developers that have deep expertise in the field of obesity, the function of MetAP2 inhibitors and metabolic diseases; maintaining flexibility in commercializing and maximizing the value of development programs; and developing other potential product candidates. Intellectual Property The company’s owned and licensed patents and patent applications relate to beloranib compositions of matter, formulations, polymorphs, methods of treating obesity using dosing regimens of beloranib and methods of treating hypothalamic obesity. The issued U.S. and European patents generally directed to beloranib compositions of matter are exclusively licensed and would each expire in 2019. The company owns an issued U.S. patent relating to beloranib polymorph compositions of matter that would expire in 2031 and an issued U.S. patent to methods of treating obesity that would expire in 2029. As of February 28, 2014, the company owned two issued U.S. patents, eight pending U.S. patent applications and foreign counterpart applications, and one Patent Cooperation Treaty (PCT) application, all of which relate to beloranib. As of February 28, 2014, the company owned seven pending U.S. patent applications with pending foreign counterpart applications and five PCT patent applications, all of which relate to MetAP2 inhibitor program. Of these, one pending U.S. patent application with pending foreign counterpart patent applications and one PCT patent application relate to early-stage product candidate ZGN-839. As of February 28, 2014, the company owned two pending U.S patent applications with pending foreign counterpart patent applications, one pending PCT patent application and two U.S. provisional patent applications that relate to second-generation MetAP2 inhibitor program. The company owns various U.S. federal trademark registrations and applications and unregistered trademarks, including the following trademarks: ZAFGEN and corporate logo. History Zafgen, Inc. was founded in 2005. The company was incorporated under the laws of the state of Delaware in 2005.
zafgen inc (ZA7:Frankfurt)
175 Portland Street
Boston, MA 02114
|No competitor information is available for ZA7.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ZAFGEN INC, please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.